ArticleJAMA oncology2023

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.

Mariano Provencio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.